{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:31:29Z","timestamp":1792798289547,"version":"4.5.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The purpose of this work is to provide an\n                    <jats:italic>in silico<\/jats:italic>\n                    molecular rationale of the role eventually played by currently circulating mutations in the receptor binding domain of the SARS-CoV-2 spike protein (S-RBD\n                    <jats:sub>CoV\u20112<\/jats:sub>\n                    ) in evading the immune surveillance effects elicited by the two Eli Lilly LY-CoV555\/bamlanivimab and LY-CoV016\/etesevimab monoclonal antibodies. The main findings from this study show that, compared to the wild-type SARS-CoV-2 spike protein, mutations E484A\/G\/K\/Q\/R\/V, Q493K\/L\/R, S494A\/P\/R, L452R and F490S are predicted to be markedly resistant to neutralization by LY-CoV555, while mutations K417E\/N\/T, D420A\/G\/N, N460I\/K\/S\/T, T415P, and Y489C\/S are predicted to confer LY-CoV016 escaping advantage to the viral protein. A challenge of our global\n                    <jats:italic>in silico<\/jats:italic>\n                    results against relevant experimental data resulted in an overall 90% agreement. Thus, the results presented provide a molecular-based rationale for all relative experimental findings, constitute a fast and reliable tool for identifying and prioritizing all present and newly reported circulating spike SARS-CoV-2 variants with respect to antibody neutralization, and yield substantial structural information for the development of next-generation vaccines and monoclonal antibodies more resilient to viral evolution.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-99827-3","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T09:24:52Z","timestamp":1634030692000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies"],"prefix":"10.1038","volume":"11","author":[{"given":"Erik","family":"Laurini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Marson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"Aulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fermeglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Pricl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"99827_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu, B., Guo, H., Zhou, P. & Shi, Z.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141\u2013154 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"99827_CR2","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): A review. JAMA 324, 782\u2013793 (2020).","journal-title":"JAMA"},{"key":"99827_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel Coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"99827_CR4","unstructured":"https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports (2021)."},{"key":"99827_CR5","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jama.2019.20153","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): A review. JAMA 323, 1824\u20131836 (2020).","journal-title":"JAMA"},{"key":"99827_CR6","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3389\/fimmu.2020.01708","volume":"11","author":"Y Tang","year":"2020","unstructured":"Tang, Y. et al. Cytokine storm in COVID-19: The current evidence and treatment strategies. Front. Immunol. 11, 1708. https:\/\/doi.org\/10.3389\/fimmu.2020.01708 (2020).","journal-title":"Front. Immunol."},{"key":"99827_CR7","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamainternmed.2020.3313","volume":"180","author":"P Sinha","year":"2020","unstructured":"Sinha, P., Matthay, M. A. & Calfee, C. S. Is a \u201ccytokine storm\u201d relevant to COVID-19?. JAMA Intern. Med. 180, 1152\u20131154 (2020).","journal-title":"JAMA Intern. Med."},{"key":"99827_CR8","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","volume":"28","author":"G Forni","year":"2021","unstructured":"Forni, G. et al. COVID-19 vaccines: Where we stand and challenges ahead. Cell Death Differ. 28, 626\u2013639 (2021).","journal-title":"Cell Death Differ."},{"key":"99827_CR9","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1021\/acscentsci.1c00120","volume":"7","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. A comprehensive review of the global efforts on COVID-19 vaccine development. ACS Cent. Sci. 7, 512\u2013533 (2021).","journal-title":"ACS Cent. Sci."},{"key":"99827_CR10","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1038\/s41467-020-18450-4","volume":"11","author":"AT Huang","year":"2020","unstructured":"Huang, A. T. et al. A systematic review of antibody mediated immunity to coronaviruses: Kinetics, correlates of protection, and association with severity. Nat. Commun. 11, 4704. https:\/\/doi.org\/10.1038\/s41467-020-18450-4 (2020).","journal-title":"Nat. Commun."},{"key":"99827_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","volume":"41","author":"S Jiang","year":"2020","unstructured":"Jiang, S., Hillyer, C. & Du, L. Neutralizing antibodies against SARS-CoV-2 and other human Coronaviruses. Trends Immunol. 41, 355\u2013359 (2020).","journal-title":"Trends Immunol."},{"key":"99827_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-biophys-062920-063711","volume":"50","author":"J Chen","year":"2021","unstructured":"Chen, J., Gao, K., Wang, R., Nguyen, D. D. & Wei, G. W. Review of COVID-19 antibody therapies. Annu. Rev. Biophys. 50, 1\u201330 (2021).","journal-title":"Annu. Rev. Biophys."},{"key":"99827_CR13","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.aad5224","volume":"351","author":"D Corti","year":"2016","unstructured":"Corti, D. et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351, 1339\u20131342 (2016).","journal-title":"Science"},{"key":"99827_CR14","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1001\/jamainternmed.2020.4624","volume":"180","author":"MH Katz","year":"2020","unstructured":"Katz, M. H. Neutralizing antibodies against SARS-CoV-2\u2014Important questions, unclear answers. JAMA Intern. Med. 180, 1362\u20131362 (2020).","journal-title":"JAMA Intern. Med."},{"key":"99827_CR15","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/s41587-020-0732-8","volume":"38","author":"L DeFrancesco","year":"2020","unstructured":"DeFrancesco, L. COVID-19 antibodies on trial. Nat. Biotechnol. 38, 1242\u20131252 (2020).","journal-title":"Nat. Biotechnol."},{"key":"99827_CR16","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.7150\/ijbs.59149","volume":"17","author":"L Ning","year":"2021","unstructured":"Ning, L., Abagna, H. B., Jiang, Q., Liu, S. & Huang, J. Development and application of therapeutic antibodies against COVID-19. Int. J. Biol. Sci. 17, 1486\u20131496 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"99827_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3584","volume":"370","author":"E Mahase","year":"2020","unstructured":"Mahase, E. Covid-19: RECOVERY trial will evaluate \u201cantiviral antibody cocktail\u201d. BMJ 370, m3584. https:\/\/doi.org\/10.1136\/bmj.m3584 (2020).","journal-title":"BMJ"},{"key":"99827_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"PC Taylor","year":"2021","unstructured":"Taylor, P. C. et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 21, 382\u2013393 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"99827_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3390\/antib2030452","volume":"2","author":"S Goswami","year":"2013","unstructured":"Goswami, S., Wang, W., Arakawa, T. & Ohtake, S. Developments and challenges for mAb-based therapeutics. Antibodies 2, 452\u2013500 (2013).","journal-title":"Antibodies"},{"key":"99827_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","volume":"27","author":"R-M Lu","year":"2020","unstructured":"Lu, R.-M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27, 1. https:\/\/doi.org\/10.1186\/s12929-019-0592-z (2020).","journal-title":"J. Biomed. Sci."},{"key":"99827_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281\u2013292 (2020).","journal-title":"Cell"},{"key":"99827_CR22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1126\/science.abe1502","volume":"370","author":"S Bangaru","year":"2020","unstructured":"Bangaru, S. et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science 370, 1089\u20131094 (2020).","journal-title":"Science"},{"key":"99827_CR23","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"99827_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"99827_CR25","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444\u20131448 (2020).","journal-title":"Science"},{"key":"99827_CR26","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","volume":"181","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181, 894\u2013904 (2020).","journal-title":"Cell"},{"key":"99827_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41586-020-2772-0","volume":"588","author":"DJ Benton","year":"2020","unstructured":"Benton, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327\u2013330 (2020).","journal-title":"Nature"},{"key":"99827_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 (2020).","journal-title":"Cell"},{"key":"99827_CR29","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.REV120.015980","volume":"296","author":"P Fuentes-Prior","year":"2021","unstructured":"Fuentes-Prior, P. Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection. J. Biol. Chem. 296, 100135. https:\/\/doi.org\/10.1074\/jbc.REV120.015980 (2021).","journal-title":"J. Biol. Chem."},{"key":"99827_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2020.102125","volume":"50","author":"S Xiaojie","year":"2021","unstructured":"Xiaojie, S., Yu, L., Lei, Y., Guang, Y. & Min, Q. Neutralizing antibodies targeting SARS-CoV-2 spike protein. Stem Cell Res. 50, 102125. https:\/\/doi.org\/10.1016\/j.scr.2020.102125 (2021).","journal-title":"Stem Cell Res."},{"key":"99827_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.671633","volume":"8","author":"L Min","year":"2021","unstructured":"Min, L. & Sun, Q. Antibodies and vaccines target RBD of SARS-CoV-2. Front. Mol. Biosci. 8, 671633. https:\/\/doi.org\/10.3389\/fmolb.2021.671633 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"99827_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21609-2","volume":"12","author":"F Bertoglio","year":"2021","unstructured":"Bertoglio, F. et al. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nat. Commun. 12, 1577. https:\/\/doi.org\/10.1038\/s41467-021-21609-2 (2021).","journal-title":"Nat. Commun."},{"key":"99827_CR33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41392-020-00318-0","volume":"5","author":"F Yu","year":"2020","unstructured":"Yu, F. et al. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal. Transduct. Target. Ther. 5, 212. https:\/\/doi.org\/10.1038\/s41392-020-00318-0 (2020).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"99827_CR34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"99827_CR35","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024-1042.e1021. https:\/\/doi.org\/10.1016\/j.cell.2020.09.037 (2020).","journal-title":"Cell"},{"key":"99827_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe0367","volume":"5","author":"AS Iyer","year":"2020","unstructured":"Iyer, A. S. et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci. Immunol. 5, eabe0367. https:\/\/doi.org\/10.1126\/sciimmunol.abe0367 (2020).","journal-title":"Sci. Immunol."},{"key":"99827_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41423-020-0458-z","volume":"17","author":"C Yi","year":"2020","unstructured":"Yi, C. et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell. Mol. Immunol. 17, 621\u2013630 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"99827_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf1906","volume":"13","author":"BE Jones","year":"2021","unstructured":"Jones, B. E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci. Trans. Med. 13, eabf1906. https:\/\/doi.org\/10.1126\/scitranslmed.abf1906 (2021).","journal-title":"Sci. Trans. Med."},{"key":"99827_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120\u2013124 (2020).","journal-title":"Nature"},{"key":"99827_CR40","unstructured":"NCT04411628: A study of LY3819253 (LY-CoV555) in participants hospitalized for COVID-19. Official title: A randomized, placebo-controlled, double-blind, sponsor unblinded, single ascending dose, phase 1 first in human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous LY3819253 in participants hospitalized for COVID-19. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04411628 (2021)."},{"key":"99827_CR41","unstructured":"NCT04427501: A study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in participants with mild to moderate COVID-19 illness (BLAZE-1). Official title: A randomized, double-blind, placebo-controlled, phase 2\/3 study to evaluate the efficacy and safety of LY3819253 and LY3832479 in participants with mild to moderate COVID-19 illness. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04427501 (2021)."},{"key":"99827_CR42","unstructured":"NCT04497987: A study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in preventing SARS-CoV-2 infection and COVID-19 in nursing home residents and staff (BLAZE-2). Official title: A phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of LY3819253 alone and in combination with LY3832479 in preventing SARS-CoV-2 infection and COVID-19 in skilled nursing and assisted living facility residents and staff; a NIAID and Lilly Collaborative Study. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04497987 (2021)."},{"key":"99827_CR43","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41579-020-00449-9","volume":"19","author":"JE Jones","year":"2021","unstructured":"Jones, J. E., Le Sage, V. & Lakdawala, S. S. Viral and host heterogeneity and their effects on the viral life cycle. Nat. Rev. Microbiol. 19, 272\u2013282 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"99827_CR44","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.molcel.2020.07.027","volume":"79","author":"F Robson","year":"2020","unstructured":"Robson, F. et al. Coronavirus RNA proofreading: Molecular basis and therapeutic targeting. Mol. Cell 79, 710\u2013727 (2020).","journal-title":"Mol. Cell"},{"key":"99827_CR45","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V\u2019kovski","year":"2021","unstructured":"V\u2019kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155\u2013170 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"99827_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01031-17","volume":"92","author":"KM Peck","year":"2018","unstructured":"Peck, K. M. & Lauring, A. S. Complexities of viral mutation rates. J. Virol. 92, e01031-17. https:\/\/doi.org\/10.1128\/jvi.01031-17 (2018).","journal-title":"J. Virol."},{"key":"99827_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb5813","volume":"6","author":"S Di Giorgio","year":"2020","unstructured":"Di Giorgio, S., Martignano, F., Torcia, M. G., Mattiuz, G. & Conticello, S. G. Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2. Sci. Adv. 6, eabb813. https:\/\/doi.org\/10.1126\/sciadv.abb5813 (2020).","journal-title":"Sci. Adv."},{"key":"99827_CR48","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41564-020-0690-4","volume":"5","author":"ND Grubaugh","year":"2020","unstructured":"Grubaugh, N. D., Petrone, M. E. & Holmes, E. C. We shouldn\u2019t worry when a virus mutates during disease outbreaks. Nat. Microbiol. 5, 529\u2013530 (2020).","journal-title":"Nat. Microbiol."},{"key":"99827_CR49","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/d41586-021-00065-4","volume":"589","author":"D Cyranoski","year":"2021","unstructured":"Cyranoski, D. Alarming COVID variants show vital role of genomic surveillance. Nature 589, 337\u2013338 (2021).","journal-title":"Nature"},{"key":"99827_CR50","unstructured":"https:\/\/www.gisaid.org\/ (2021)."},{"key":"99827_CR51","unstructured":"https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/variants\/variant-info.html (2021)."},{"key":"99827_CR52","unstructured":"https:\/\/www.ecdc.europa.eu\/en\/covid-19\/variants-concern (2021)."},{"key":"99827_CR53","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","volume":"21","author":"D Cromer","year":"2021","unstructured":"Cromer, D. et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat. Rev. Immunol. 21, 395\u2013404 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"99827_CR54","first-page":"285","volume":"3","author":"Y Huang","year":"2020","unstructured":"Huang, Y. et al. Neutralizing antibodies against SARS-CoV-2: Current understanding, challenge and perspective. Antib. Ther. 3, 285\u2013299 (2020).","journal-title":"Antib. Ther."},{"key":"99827_CR55","doi-asserted-by":"publisher","first-page":"11821","DOI":"10.1021\/acsnano.0c04674","volume":"14","author":"E Laurini","year":"2020","unstructured":"Laurini, E., Marson, D., Aulic, S., Fermeglia, M. & Pricl, S. Computational alanine scanning and structural analysis of the SARS-CoV-2 spike protein\/angiotensin-converting enzyme 2 complex. ACS Nano 14, 11821\u201311830 (2020).","journal-title":"ACS Nano"},{"key":"99827_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100255","volume":"2","author":"TN Starr","year":"2021","unstructured":"Starr, T. N., Greaney, A. J., Dingens, A. S. & Bloom, J. D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep. Med. 2, 100255. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100255 (2021).","journal-title":"Cell Rep. Med."},{"key":"99827_CR57","doi-asserted-by":"publisher","first-page":"6929","DOI":"10.1021\/acsnano.0c10833","volume":"15","author":"E Laurini","year":"2021","unstructured":"Laurini, E., Marson, D., Aulic, S., Fermeglia, A. & Pricl, S. Computational mutagenesis at the SARS-CoV-2 spike protein\/angiotensin-converting enzyme 2 binding interface: Comparison with experimental evidence. ACS Nano 15, 6929\u20136948 (2021).","journal-title":"ACS Nano"},{"key":"99827_CR58","unstructured":"Lilly. https:\/\/www.covid19.lilly.com\/bam-ete (2021)."},{"key":"99827_CR59","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1038\/s41467-021-24435-8","volume":"12","author":"AJ Greaney","year":"2021","unstructured":"Greaney, A. J. et al. Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies. Nat. Commun. 12, 4196. https:\/\/doi.org\/10.1038\/s41467-021-24435-8 (2021).","journal-title":"Nat. Commun."},{"key":"99827_CR60","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-228079\/v1","author":"M Diamond","year":"2021","unstructured":"Diamond, M. et al. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-228079\/v1 (2021).","journal-title":"Res. Sq."},{"key":"99827_CR61","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","volume":"27","author":"RE Chen","year":"2021","unstructured":"Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717\u2013726 (2021).","journal-title":"Nat. Med."},{"key":"99827_CR62","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130\u2013135 (2021).","journal-title":"Nature"},{"key":"99827_CR63","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1016\/S2666-5247(21)00068-9","volume":"2","author":"S Jangra","year":"2021","unstructured":"Jangra, S. et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe 2, e283\u2013e284 (2021).","journal-title":"Lancet Microbe"},{"key":"99827_CR64","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3390\/v13030392","volume":"13","author":"F Grabowski","year":"2021","unstructured":"Grabowski, F., Preibisch, G., Gizi\u0144ski, S., Kocha\u0144czyk, M. & Lipniacki, T. SARS-CoV-2 variant of concern 202012\/01 has about twofold replicative advantage and acquires concerning mutations. Viruses 13, 392. https:\/\/doi.org\/10.3390\/v13030392 (2021).","journal-title":"Viruses"},{"key":"99827_CR65","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2372\u20132383 (2021).","journal-title":"Cell"},{"key":"99827_CR66","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.chom.2021.02.003","volume":"29","author":"AJ Greaney","year":"2021","unstructured":"Greaney, A. J. et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29, 463\u2013476 (2021).","journal-title":"Cell Host Microbe"},{"key":"99827_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03908-2","author":"MK Annavajhala","year":"2021","unstructured":"Annavajhala, M. K. et al. Emergence and expansion of the SARS-CoV-2 variant B.1.526 identified in New York. Nature https:\/\/doi.org\/10.1038\/s41586-021-03908-2 (2021).","journal-title":"Nature"},{"key":"99827_CR68","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.cell.2021.02.042","volume":"184","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell 184, 2362\u20132371 (2021).","journal-title":"Cell"},{"key":"99827_CR69","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","volume":"593","author":"S Cele","year":"2021","unstructured":"Cele, S. et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature 593, 142\u2013146 (2021).","journal-title":"Nature"},{"key":"99827_CR70","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.61312","volume":"9","author":"Y Weisblum","year":"2020","unstructured":"Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife 9, e61312. https:\/\/doi.org\/10.7554\/eLife.61312 (2020).","journal-title":"Elife"},{"key":"99827_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2231","author":"D Focosi","year":"2021","unstructured":"Focosi, D. & Maggi, F. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev. Med. Virol. https:\/\/doi.org\/10.1002\/rmv.2231 (2021).","journal-title":"Rev. Med. Virol."},{"key":"99827_CR72","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1919285","volume":"13","author":"H Liu","year":"2021","unstructured":"Liu, H. et al. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro. MAbs 13, 1919285. https:\/\/doi.org\/10.1080\/19420862.2021.1919285 (2021).","journal-title":"MAbs"},{"key":"99827_CR73","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","volume":"29","author":"Z Liu","year":"2021","unstructured":"Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477\u2013488 (2021).","journal-title":"Cell Host Microbe"},{"key":"99827_CR74","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","volume":"184","author":"W Dejnirattisai","year":"2021","unstructured":"Dejnirattisai, W. et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184, 2939\u20132954 (2021).","journal-title":"Cell"},{"key":"99827_CR75","doi-asserted-by":"publisher","first-page":"ofab300","DOI":"10.1093\/ofid\/ofab300","volume":"8","author":"AM Moustafa","year":"2021","unstructured":"Moustafa, A. M. et al. Comparative analysis of emerging B.1.1.7+E484K SARS-CoV-2 isolates from Pennsylvania. Open Forum Infect. Dis. 8, ofab300. https:\/\/doi.org\/10.1093\/ofid\/ofab300 (2021).","journal-title":"Open Forum Infect. Dis."},{"key":"99827_CR76","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","volume":"593","author":"DA Collier","year":"2021","unstructured":"Collier, D. A. et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 593, 136\u2013141 (2021).","journal-title":"Nature"},{"key":"99827_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.167155","volume":"433","author":"J Chen","year":"2021","unstructured":"Chen, J., Gao, K., Wang, R. & Wei, G. W. Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies. Mol. Biol. 433, 167155. https:\/\/doi.org\/10.1016\/j.jmb.2021.167155 (2021).","journal-title":"Mol. Biol."},{"key":"99827_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109627","volume":"36","author":"IF Urdaniz","year":"2021","unstructured":"Urdaniz, I. F. et al. One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening. Cell Rep. 36, 109627. https:\/\/doi.org\/10.1016\/j.celrep.2021.109627 (2021).","journal-title":"Cell Rep."},{"key":"99827_CR79","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1016\/j.cell.2021.04.025","volume":"184","author":"X Deng","year":"2021","unstructured":"Deng, X. et al. Transmission, infectivity, and neutralization of a L452R SARS-CoV-2 variant. Cell 184, 3426\u20133437 (2021).","journal-title":"Cell"},{"key":"99827_CR80","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.chom.2021.06.006","volume":"29","author":"C Motozono","year":"2021","unstructured":"Motozono, C. et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe 29, 1124\u20131136 (2021).","journal-title":"Cell Host Microbe"},{"key":"99827_CR81","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1126\/science.abi7994","volume":"373","author":"M McCallum","year":"2021","unstructured":"McCallum, M. et al. SARS-CoV-2 immune evasion by the B.1.427\/B.1.429 variant of concern. Science 373, 648\u2013654 (2021).","journal-title":"Science"},{"key":"99827_CR82","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","volume":"182","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182, 1284\u20131294 (2020).","journal-title":"Cell"},{"key":"99827_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109415","volume":"36","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 36, 109415. https:\/\/doi.org\/10.1016\/j.celrep.2021.109415 (2021).","journal-title":"Cell Rep."},{"key":"99827_CR84","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41591-021-01347-0","volume":"27","author":"E Andreano","year":"2021","unstructured":"Andreano, E. & Rappuoli, R. SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. Nat. Med. 27, 759\u2013761 (2021).","journal-title":"Nat. Med."},{"key":"99827_CR85","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","volume":"27","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 27, 917\u2013924 (2021).","journal-title":"Nat. Med."},{"key":"99827_CR86","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med."},{"key":"99827_CR87","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med"},{"key":"99827_CR88","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/d41586-021-00241-6","volume":"590","author":"E Callaway","year":"2021","unstructured":"Callaway, E. & Ledford, H. How to redesign COVID vaccines so they protect against variants. Nature 590, 15\u201316 (2021).","journal-title":"Nature"},{"key":"99827_CR89","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/cvr\/cvy040","volume":"114","author":"E Laurini","year":"2018","unstructured":"Laurini, E. et al. Biomechanical defects and rescue of cardiomyocytes expressing pathologic nuclear lamins. Cardiovasc. Res. 114, 846\u2013857 (2018).","journal-title":"Cardiovasc. Res."},{"key":"99827_CR90","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/1878-0261.12101","volume":"11","author":"C Colombo","year":"2017","unstructured":"Colombo, C. et al. \u03b2-Catenin in desmoid-type fibromatosis: Deep insights into the role of T41A and S45F mutations on protein structure and gene expression. Mol. Oncol. 11, 1495\u20131507 (2017).","journal-title":"Mol. Oncol."},{"key":"99827_CR91","doi-asserted-by":"publisher","first-page":"E4924","DOI":"10.1073\/pnas.1615730114","volume":"114","author":"D Genini","year":"2017","unstructured":"Genini, D. et al. Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells. Proc. Natl. Acad. Sci. U.S.A. 114, E4924\u2013E4933 (2017).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"99827_CR92","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.mrfmmm.2015.09.002","volume":"781","author":"A Morgan","year":"2015","unstructured":"Morgan, A. et al. Target sequencing approach intended to discover new mutations in non-syndromic intellectual disability. Mutat. Res. 781, 32\u201336 (2015).","journal-title":"Mutat. Res."},{"key":"99827_CR93","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1073\/pnas.1321173111","volume":"111","author":"D Gibbons","year":"2014","unstructured":"Gibbons, D. et al. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc. Natl. Acad. Sci. U.S.A. 111, 3550\u20133555 (2014).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"99827_CR94","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1021\/bi401575g","volume":"53","author":"S Brune","year":"2014","unstructured":"Brune, S. et al. The sigma enigma: In vitro\/in silico site-directed mutagenesis studies unveil \u03c31 receptor ligand binding. Biochemistry 53, 2993\u20133003 (2014).","journal-title":"Biochemistry"},{"key":"99827_CR95","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/labinvest.2013.107","volume":"93","author":"F Bozzi","year":"2013","unstructured":"Bozzi, F. et al. In vitro and in silico studies of MDM2\/MDMX isoforms predict Nutlin-3A sensitivity in well\/de-differentiated liposarcomas. Lab. Investig. 93, 1232\u20131240 (2013).","journal-title":"Lab. Investig."},{"key":"99827_CR96","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrclinonc.2011.3","volume":"8","author":"MA Pierotti","year":"2011","unstructured":"Pierotti, M. A., Tamborini, E., Negri, T., Pricl, S. & Pilotti, S. Targeted therapy in GIST: In silico modeling for prediction of resistance. Nat. Rev. Clin. Oncol. 8, 161\u2013170 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"99827_CR97","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res. 28, 235\u2013242 (2000).","journal-title":"Nucleic Acids Res."},{"key":"99827_CR98","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/nar\/gks375","volume":"40","author":"R Anandakrishnan","year":"2012","unstructured":"Anandakrishnan, R., Aguilar, B. & Onufriev, A. V. H++ 3.0: Automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations. Nucleic Acids Res. 40, 537\u2013541 (2012).","journal-title":"Nucleic Acids Res."},{"key":"99827_CR99","volume-title":"AMBER 2020","author":"DA Case","year":"2019","unstructured":"Case, D. A. et al. AMBER 2020 (University of California, 2019)."},{"key":"99827_CR100","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier, J. A. et al. ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. 11, 3696\u20133713 (2015).","journal-title":"J. Chem. Theory Comput."},{"key":"99827_CR101","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/jcc.20820","volume":"29","author":"KN Kirschner","year":"2008","unstructured":"Kirschner, K. N. et al. GLYCAM06: A generalizable biomolecular force field. Carbohydrates. J. Comput. Chem. 29, 622\u2013655 (2008).","journal-title":"J. Comput. Chem."},{"key":"99827_CR102","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1063\/1.445869","volume":"79","author":"WL Jorgensen","year":"1983","unstructured":"Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926\u2013935 (1983).","journal-title":"J. Chem. Phys."},{"key":"99827_CR103","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1063\/1.448118","volume":"81","author":"HJC Berendsen","year":"1984","unstructured":"Berendsen, H. J. C., Postma, J. P. M., Gunsteren, W. F. V., DiNola, A. & Haak, J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684\u20133690 (1984).","journal-title":"J. Chem. Phys."},{"key":"99827_CR104","doi-asserted-by":"publisher","first-page":"10913","DOI":"10.1063\/1.1324708","volume":"113","author":"A Toukmaji","year":"2000","unstructured":"Toukmaji, A., Sagui, C., Board, J. & Darden, T. Efficient particle-mesh Ewald based approach to fixed and induced dipolar interactions. J. Chem. Phys. 113, 10913\u201310927 (2000).","journal-title":"J. Chem. Phys."},{"key":"99827_CR105","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/bip.360320508","volume":"32","author":"RJ Loncharich","year":"1992","unstructured":"Loncharich, R. J., Brooks, B. R. & Pastor, R. W. Langevin dynamics of peptides: The frictional dependence of isomerization rates of N-acetylalanyl-N\u2032-methylamide. Biopolymers 32, 523\u2013535 (1992).","journal-title":"Biopolymers"},{"key":"99827_CR106","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","volume":"23","author":"J-P Ryckaert","year":"1977","unstructured":"Ryckaert, J.-P., Ciccotti, G. & Berendsen, H. J. C. Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. J. Comput. Phys. 23, 327\u2013341 (1977).","journal-title":"J. Comput. Phys."},{"key":"99827_CR107","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2014A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"99827_CR108","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey, W., Dalke, A. & Schulten, K. V. M. D. Visual molecular dynamics. J. Mol. Graph. 14, 33\u201338 (1996).","journal-title":"J. Mol. Graph."},{"key":"99827_CR109","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1021\/acs.jcim.6b00734","volume":"57","author":"Y Yan","year":"2017","unstructured":"Yan, Y., Yang, M., Ji, C. G. & Zhang, J. Z. H. Interaction entropy for computational alanine scanning. J. Chem. Inf. Model. 57, 1112\u20131122 (2017).","journal-title":"J. Chem. Inf. Model."},{"key":"99827_CR110","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.1021\/jacs.6b02682","volume":"138","author":"L Duan","year":"2016","unstructured":"Duan, L., Liu, X. & Zhang, J. Z. H. Interaction entropy: A new paradigm for highly efficient and reliable computation of protein\u2013ligand binding free energy. J. Am. Chem. Soc. 138, 5722\u20135728 (2016).","journal-title":"J. Am. Chem. Soc."},{"key":"99827_CR111","doi-asserted-by":"publisher","DOI":"10.1063\/1.4978893","volume":"146","author":"Z Sun","year":"2017","unstructured":"Sun, Z., Yan, Y. N., Yang, M. & Zhang, J. Z. H. Interaction entropy for protein\u2013protein binding. J. Chem. Phys. 146, 124124. https:\/\/doi.org\/10.1063\/1.4978893 (2017).","journal-title":"J. Chem. Phys."},{"key":"99827_CR112","doi-asserted-by":"publisher","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","volume":"119","author":"E Wang","year":"2019","unstructured":"Wang, E. et al. End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: Strategies and applications in drug design. Chem. Rev. 119, 9478\u20139508 (2019).","journal-title":"Chem. Rev."},{"key":"99827_CR113","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/jcc.20566","volume":"28","author":"IS Moreira","year":"2007","unstructured":"Moreira, I. S., Fernandes, P. A. & Ramos, M. J. Computational alanine scanning mutagenesis\u2014An improved methodological approach. J. Comput. Chem. 28, 644\u2013654 (2007).","journal-title":"J. Comput. Chem."},{"key":"99827_CR114","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1021\/acs.jcim.6b00378","volume":"57","author":"IC Sim\u00f5es","year":"2017","unstructured":"Sim\u00f5es, I. C., Costa, I. P., Coimbra, J. T., Ramos, M. J. & Fernandes, P. A. New parameters for higher accuracy in the computation of binding free energy differences upon alanine scanning mutagenesis on protein\u2013protein interfaces. J. Chem. Inf. Model. 57, 60\u201372 (2017).","journal-title":"J. Chem. Inf. Model."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99827-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99827-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99827-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T08:59:57Z","timestamp":1706173197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99827-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":114,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["99827"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-99827-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.05.18.444605","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"13 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20274"}}